Prokidney (PROK) Long-Term Deferred Tax (2022 - 2023)
Prokidney (PROK) reported Long-Term Deferred Tax of $1.5 million for Q4 2023, down 15.12% year-over-year from $1.8 million in Q4 2022, and down 15.12% quarter-over-quarter from $1.8 million in Q4 2022.
Prokidney (PROK) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
Prokidney (PROK) has 2 years of Long-Term Deferred Tax data on file, last reported at $1.5 million in Q4 2023.
- Long-Term Deferred Tax for Q4 2023 came in at $1.5 million, down 15.12% year-over-year; the trailing twelve-month figure through Dec 2023 was $1.5 million (down 15.12% YoY), and the FY2023 annual result was $1.5 million, down 15.12% from the prior year.
- Long-Term Deferred Tax eased to $1.5 million in Q4 2023 per PROK's latest filing, from $1.8 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $1.8 million in Q4 2022 and troughed at $1.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Prokidney | 259.01 Mn | 1.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.49 Mn |
| Dec 31, 2022 | 1.76 Mn |